2-(2-chlorophenylmethyl)-2-imidazoline | 65248-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-chlorophenylmethyl)-2-imidazoline
• 英文别名: 2-(2-chlorophenyl)methylimidazoline；2-(2-Chlor-benzyl)-imidazolin；2-(2-Chlor-benzyl)-Δ²-imidazolin；2-(2-chloro-benzyl)-4,5-dihydro-1H-imidazole；2-(2-Chlorophenyl)methyl-imidazoline；2-[(2-chlorophenyl)methyl]-4,5-dihydro-1H-imidazole
• CAS: 65248-55-7
• 化学式: C₁₀H₁₁ClN₂
• 分子量: 194.664
• InChiKey: MLAOOFCCEBANQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-chlorophenylmethyl)-2-imidazoline 在 potassium tert-butylate 、 二异丙胺 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 反应 8.0h， 生成 10-(2-chlorophenyl)-2,3-dihydroimidazo<1,2-g><1,6>naphthyridin-5(1H)-one
  参考文献：
  名称：

  咪唑并嘧啶并[1,2- g ] [1,6]萘啶酮的合成

  摘要：

  芳基甲基咪唑啉和（3-氯苯基）甲基-1,4,5,6-四氢嘧啶酰胺化2-氯-3-吡啶羰基氯，叔丁醇钾将产物环化为线性稠合的三环咪唑基和嘧啶基[1,2- g ] [1,6]萘啶酮。2-氯-3-吡啶甲酸乙酯与2-（苯基甲基）咪唑啉在甲醇钠存在下的缩合反应直接形成异构的，有角熔融的8,9-二氢-6-苯基咪唑[1,2- a ] [1,8萘啶-5（7 H-一。

  DOI：

  10.1002/jhet.5570270214
• 作为产物：
  描述：

  乙二胺 、 1-氯-2-(2,2-二溴乙烯基)苯 反应 6.0h， 以95%的产率得到2-(2-chlorophenylmethyl)-2-imidazoline
  参考文献：
  名称：

  A novel synthetic method for 2-arylmethyl substituted imidazolines and imidazoles from 2-aryl-1,1-dibromoethenes

  摘要：

  Various 2-arylmethylimidazolines were prepared by treating readily available 2-aryl-1, 1-dibromoethenes with ethylenediamine under mild conditions and further converted into the corresponding imidazoles smoothly with Swern oxidation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.08.035

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine
  申请人：Schering Corporation

  公开号：US05070086A1

  公开（公告）日：1991-12-03

  Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds, methods of making said compounds and their use as anti-allergy, antiinflammatory and/or agents for the treatment of hyperproliferative skin disease are disclosed.

  咪唑基和嘧啶基喹啉、萘啉和吡啶吡嗪化合物的制备方法，以及它们作为抗过敏、抗炎和/或治疗过度增生性皮肤疾病的药物的用途被披露。
• Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds
  申请人：SCHERING CORPORATION

  公开号：EP0325048A1

  公开（公告）日：1989-07-26

  Compounds having the structural formula I or a pharmaceutically acceptable salts or solvates thereof, wherein: the dotted lines ---- in ring t either both represent double bonds or such double bonds are absent; X and Y each independently represent CH₂ or NR³ if the dotted line attached thereto does not represent a double bond or CH or N if the dotted line attached thereto represents a double bond; Z represents O, S or NR⁵; n represents an integer 2, 3, 4 or 5; R¹ and R² may be the same or different and each R¹ and each R² independently represents H or alkyl or two R¹ and R² groups on the same or different carbon atoms may together represent a carbocyclic ring having from 5 to 8 carbon atoms; each R³ independently represents H, alkyl, aralkyl, heteroarylalkyl, acyl, aroyl or heteroaroyl; R⁴ represents H, alkyl, aryl, aralkyl or heteroaryl; and R⁵ represents H, alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, acyl, aroyl or heteraroyl, methods of making said compounds and their use as anti-allergy, antiinflammatory and/or agents for the treatment of hyperproliferative skin disease are disclosed.

  具有结构式 I 的化合物 或其药学上可接受的盐或溶液，其中 环 t 中的虚线 ---- 均代表双键或不代表双键； X和Y各自独立地代表CH₂或NR³（如果所附的虚线不代表双键）或CH或N（如果所附的虚线代表双键）； Z 代表 O、S 或 NR⁵； n 代表整数 2、3、4 或 5； R¹ 和 R² 可以相同或不同，每个 R¹ 和每个 R² 独立地代表 H 或烷基，或者位于相同或不同碳原子上的两个 R¹ 和 R² 基团可以共同代表一个具有 5 至 8 个碳原子的碳环； 每个 R³ 独立地代表 H、烷基、芳烷基、杂芳烷基、酰基、芳基或杂芳基； R⁴ 代表 H、烷基、芳基、芳烷基或杂芳基；以及 R⁵ 代表 H、烷基、芳基、杂芳基、芳烷基、杂芳烷基、酰基、酰基或杂芳基，公开了制造所述化合物的方法及其作为抗过敏、抗炎和/或治疗过度增生性皮肤病的药物的用途。
• FRIARY, R.;SCHWERDT, J. H.;SEIDL, V.;VILLANI, F. J., J. HETEROCYCL. CHEM., 27,(1990) N, C. 189-193
  作者：FRIARY, R.、SCHWERDT, J. H.、SEIDL, V.、VILLANI, F. J.

  DOI：——

  日期：——
• EP1981497A2
  申请人：——

  公开号：EP1981497A2

  公开（公告）日：2008-10-22